The Lung Trans study aims to develop a greater understanding of lung cancer outcomes by performing molecular and non-molecular profiling of samples to examine biomarkers in patients with lung cancer.  The study will initially utilise biological samples from three lung cancer studies (TACTIC, TOPICAL, and ET) which are now closed; samples from other approved studies will be added over time.  We will investigate how these biomarkers are associated with clinical outcomes such as progression and death (prognostic factors), and whether they could be used as predictive markers to predict how well patients respond to different treatments.